USP7 and acute myeloid leukemia: In AML, Cartel and colleagues reported that the early USP7 inhibitor P22077 reduces viability of primary AML cells in vitro and tumor burden in vivo in PDX (patient-derived xenograft) models, and suggested USP7-mediated stabilization of CHK1 as one mechanism contributing to cytotoxicity [264].